summit trial tirzepatide results Effects of on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the Efficacy and safety of a

Notify your doctor if these symptoms last for more than a few days or if you have trouble taking liquids by mouth

Stubborn Fat Deposits: Even after substantial weight loss, some fat pockets may remain in areas like the abdomen, thighs, or arms

Who GLP-1 weight loss is for - and who it isn't Patients we typically work with on GLP-1 weight management: Adults with BMI 30+ (obesity) who have not achieved sustained weight loss with lifestyle change alone Adults with BMI 27+ and weight-related comorbidities - type 2 diabetes, hypertension, dyslipidemia, sleep apnea, prediabetes, fatty liver disease Patients with insulin resistance or metabolic syndrome where the metabolic and weight pictures are intertwined Patients post-bariatric surgery with weight regain, where appropriate and coordinated with their surgical team GLP-1 medications are not appropriate for patients with personal or family history of medullary thyroid carcinoma, MEN2 syndrome, history of pancreatitis, severe gastroparesis, or active eating disorders

ALL CLINICAL DECISIONS ARE MADE BY INDEPENDENT PROVIDERS, AND ALL MEDICATIONS ARE PREPARED AND DISPENSED BY INDEPENDENT LICENSED PHARMACIES

It has, in many ways, become a real-time experiment happening in each individual body

This ensures the clinical rationale for therapy is documented and supports consistent adjudication